A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Mechanism of action

Evidence map: Bacopa monnieri

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

A review names antioxidant cell protection, inhibition of acetylcholinesterase or activation of choline acetyltransferase, less beta-amyloid, greater cerebral blood flow, and changes in acetylcholine, serotonin, and dopamine as presumed mechanisms; most of the data come from animal and cell studies [1]. In mice with the olfactory bulb removed, a model of memory impairment, a bacopa extract reversed memory deficits, preserved cholinergic neurons, increased BDNF mRNA in the hippocampus, and inhibited acetylcholinesterase in brain tissue; the muscarinic receptor blocker scopolamine abolished the effect on short-term memory [2]. In cultures of cortical neurons, the extract protected against beta-amyloid but not against glutamate and reduced reactive oxygen species [3].

In humans, bacopa does not act acutely but was mostly tested over twelve weeks. A meta-analysis of nine RCTs with 518 participants found faster completion of the Trail Making Test B and shorter choice reaction times [4]. A systematic review of six RCTs in adults without dementia found improvements in 9 of 17 tests of free recall but few effects in other domains [5]. Individual RCTs showed slower forgetting of newly learned information in people aged 40 to 65 [6] and better delayed word recall in healthy older adults [7][8].

Targets

TargetTypeActionKey dataEvidence
AcetylcholinesteraseEnzymeInhibitor Animal study[2][3]
Choline acetyltransferase / cholinergic neuronsEnzymeExpression ↑ Animal study[2]
BDNF transcription, CREB phosphorylationSignaling pathwayActivator Animal study[2]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamineno data
  • Noradrenalineno data
  • Serotoninmodulated · according to the review from animal studies; not checked in detail[1]
  • Acetylcholine↑ · Acetylcholinesterase inhibited, cholinergic neurons preserved (mouse, cell culture)[2][3]
  • Glutamate · AMPAno data
  • Glutamate · NMDAno data
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophins↑ · BDNF mRNA and CREB phosphorylation increased in the hippocampus (mouse)[2]
  • Blood flow↑ · greater cerebral blood flow according to the review (animal data); not checked in detail[1]
  • Nitric oxideno data
  • Energy metabolismno data
  • Insulin · glucoseno data
  • Inflammation · oxidative↓ · fewer reactive oxygen species, protection against beta-amyloid (cell culture)[3]
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Human studies

  • Meta-analysis, cognition

    Meta-analysis of 9 RCTs (at least 12 weeks) · not stated in the abstract · n = 518 · ≥ 12 weeks

    Measured: Trail Making Test B, choice reaction time

    Result: Trail B faster, choice reaction time shorter by 10.6 ms; low risk of bias.[4]

    Human, randomised

  • Systematic review in adults without dementia

    systematic review of 6 RCTs · healthy (adults without dementia) · 12 weeks

    Measured: validated cognitive tests

    Result: Improvement in 9 of 17 tests of free recall; little evidence for other domains.[5]

    Human, randomised

  • Memory in people aged 40 to 65

    RCT, double-blind, placebo-controlled · healthy (40–65 years) · n = 76 · 3 months

    Measured: various memory functions, anxiety

    Result: Better retention of new information; attention, short-term memory, and anxiety unchanged.[6]

    Human, randomised

  • Healthy older adults, USA

    RCT, double-blind, placebo-controlled · healthy (65 years and older) · n = 54 · 12 weeks

    Measured: delayed word recall (AVLT)

    Result: Better delayed recall and Stroop test; stomach complaints as the most common adverse effect.[7]

    Human, randomised

  • Healthy older adults, Australia

    RCT, double-blind, placebo-controlled · healthy (over 55 years) · n = 98 · 12 weeks

    Measured: AVLT, Complex Figure Test, Trail Making Test, memory questionnaire

    Result: Word learning and delayed recall better; other tests not significant; more gastrointestinal adverse effects.[8]

    Human, randomised

Risks and warnings

  • Gastrointestinal complaints

    More frequent bowel movements, abdominal cramps, and nausea compared with placebo [8]; in another RCT mainly stomach complaints, about as frequent as with placebo [7].

    Human, randomised

  • Liver

    According to LiverTox, not associated with elevated liver enzymes or clinically apparent liver injury [9].

    Human, non-randomised

  • Lack of long-term data

    Long-term safety studies in humans are lacking [1].

    No data

Fact check: common claims

  • partly supported

    “Bacopa improves memory”

    Several RCTs show better free recall and slower forgetting after about twelve weeks [5][6][7][8]; other memory and thinking domains mostly remain unchanged.

  • not supported

    “Bacopa improves concentration immediately”

    The positive studies tested intake over at least twelve weeks [4][5]; evidence for acute effects was not found in the sources examined.

  • partly supported

    “Bacopa is anxiolytic”

    In healthy older adults, anxiety and depression scores fell in one RCT [7], while anxiety scores remained unchanged in another [6].

  • not supported

    “Bacopa protects against Alzheimer’s disease”

    Only cell and animal findings on beta-amyloid and cholinergic neurons [2][3]; no studies with dementia as an endpoint examined.

Pharmacokinetics

Absorption
By mouth as a standardized extract; effect in studies examined only after several weeks [5].
Half-life
Not verified.
Metabolism
Not verified.
Entry into the brain
Not verified; effects in the brain in mice after oral administration [2].

Legal status

Germany
Not verified.
EU
Not verified.
USA
Not verified; listed as a herbal product in the NIH LiverTox database [9].
Other countries
India: traditional use in Ayurvedic medicine [9]; approval status not checked.

Related compounds

Ginkgo bilobasame classRhodiola roseasame class

Open questions

  • Which constituents are responsible for the effect on memory, and how comparable are the different extracts?
  • Does the effect persist after discontinuation, and are there long-term risks?
  • Are the effects large enough to be noticeable in everyday life?

References

  1. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313–26. doi:10.1089/rej.2013.1431 · PubMed
  2. Le XT, Pham HT, Do PT, Fujiwara H, Tanaka K, Li F, et al. Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems. Neurochem Res. 2013;38(10):2201–15. doi:10.1007/s11064-013-1129-6 · PubMed
  3. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol. 2008;120(1):112–7. doi:10.1016/j.jep.2008.07.039 · PubMed
  4. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–35. doi:10.1016/j.jep.2013.11.008 · PubMed
  5. Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647–52. doi:10.1089/acm.2011.0367 · PubMed
  6. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279–81. doi:10.1016/S0893-133X(01)00419-5 · PubMed
  7. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–13. doi:10.1089/acm.2008.0018 · PubMed
  8. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753–9. doi:10.1089/acm.2009.0342 · PubMed
  9. Bacopa monnieri. In: LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012– [aktualisiert 24.04.2024]. PubMed
How this profile was checked

Last reviewed: 2026-10-23. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-23); translation checked on 2026-10-26.

Checked

  • All DOIs resolved via Crossref, PMIDs match the DOIs; [9] without a DOI, via PMID only.
  • From the abstracts: list of mechanisms, lack of long-term toxicity studies [1]; olfactory bulb model, ChAT, BDNF, CREB, AChE, scopolamine [2]; beta-amyloid, no glutamate protection, ROS [3]; 9 RCTs, 518 participants, choice reaction time −10.6 ms [4]; 6 RCTs, 9 of 17 recall tests [5]; n = 76, retention, anxiety unchanged [6]; n = 54, AVLT, Stroop, stomach complaints [7]; n = 98, AVLT, gastrointestinal adverse effects [8]; no liver enzyme elevations [9].
  • ClinicalTrials.gov: 18 entries (October 23, 2026).

Not verified

  • The Trail B effect is given in the abstract of [4] as −17.9 ms, which seems unusually small for this test; unit not checked against the full text, therefore not adopted as a number.
  • Legal status in Germany, the EU, and the USA.
  • Pharmacokinetics of bacosides in humans.

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.